Evgen Pharma (GB:TCF) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
TheraCryf plc has been awarded a European patent for its highly selective Orexin 1 receptor antagonist, a promising development in treatments for mental health conditions like anxiety and addiction. The patent enhances TheraCryf’s international intellectual property portfolio, supporting its strategy to partner with larger pharmaceutical companies for advanced trials and commercialization. This milestone could attract investors looking to capitalize on the company’s innovative neuropsychiatry and oncology pipeline.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
